Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer

INTRODUCTION. The objective of this study was to investigate clinical effectiveness and incremental lifetime costs associated with first-line bevacizumab in older patients with metastatic colorectal cancer (mCRC). METHODS. Patients diagnosed with mCRC in 2004–2007 were identified from the Surveillan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shankaran, Veena, Mummy, David, Koepl, Lisel, Bansal, Aasthaa, Mirick, Dana K., Yu, Elaine, Morlock, Rob, Ogale, Sarika, Ramsey, Scott D.
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2014
Matèries:
Outcomes Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4122470/
https://ncbi.nlm.nih.gov/pubmed/25085899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0209
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars